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Abstract
Randomized, controlled trials have demonstrated eﬃcacy for second-generation antipsychotics in the
treatment of acute mania in bipolar disorder. Despite depression being considered the hallmark of bipolar
disorder, there are no published systematic reviews or meta-analyses to evaluate the eﬃcacy of modern
atypical antipsychotics in bipolar depression. We systematically reviewed published or registered
randomized, double-blind, placebo-controlled trials (RCTs) of modern antipsychotics in adult bipolar I
and/or II depressive patients (DSM-IV criteria). Eﬃcacy outcomes were assessed based on changes in the
Montgomery–Asberg Depression Rating Scale (MADRS) during an 8-wk period. Data were combined
through meta-analysis using risk ratio as an eﬀect size with a 95% conﬁdence interval (95% CI) and with a
level of statistical signiﬁcance of 5% (p<0.05). We identiﬁed ﬁve RCTs ; four involved antipsychotic
monotherapy and one addressed both monotherapy and combination with an antidepressant. The two
quetiapine trials analysed the safety and eﬃcacy of two doses : 300 and 600 mg/d. The only olanzapine
trial assessed olanzapine monotherapy within a range of 5–20 mg/d and olanzapine–ﬂuoxetine combi-
nation within a range of 5–20 mg/d and 6–12 mg/d, respectively. The two aripiprazole placebo-controlled
trials assessed doses of 5–30 mg/d. Quetiapine and olanzapine trials (3/5, 60%) demonstrated superiority
over placebo (p<0.001). Only 2/5 (40%) (both aripiprazole trials) failed in the primary eﬃcacy measure
after the ﬁrst 6 wk. Some modern antipsychotics (quetiapine and olanzapine) have demonstrated eﬃcacy
in bipolar depressive patients from week 1 onwards. Rapid onset of action seems to be a common feature
of atypical antipsychotics in bipolar depression.
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Introduction
Randomized, placebo-controlled trials (RCTs) have
demonstrated eﬃcacy for atypical antipsychotics in
the treatment of acute mania in bipolar disorder, either
as monotherapy or adjunctive treatment (Bowden et al.
2005 ; Garcia-Amador et al. 2006 ; Hirschfeld et al. 2004 ;
Keck et al. 2003a, b ; Khanna et al. 2005; McIntyre et al.
2005 ; Potkin et al. 2005 ; Sachs et al. 2002, 2004, 2006 ;
Smulevich et al. 2005 ; Tohen et al. 1999, 2000, 2002,
2008 ; Vieta et al. 2008b, in press ; Weisler et al. 2003 ;
Yatham et al. 2003, 2007). Currently available data
suggest that combining atypical antipsychotics and
mood stabilizers is the most eﬃcacious treatment in
acute mania, reinforced after a systematic review and
meta-analysis of pooled data conducted by Perlis and
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Scherk (Perlis et al. 2006 ; Scherk et al. 2007). Atypical
antipsychotics have not traditionally been considered
as a major option in depression guidelines, unless
psychotic features were present during the acute de-
pressive episode (APA, 2002; Grunze et al. 2002, 2003;
Yatham et al. 2005b, 2006). Moreover, atypical anti-
psychotics, are generally classiﬁed as a class, despite
their marked diﬀerences in pharmacodynamic proper-
ties (D2, 5-HT, H1, a receptor aﬃnities) (Brugue &
Vieta, 2007). Based on data from the latest studies and
RCTs conducted in bipolar depression, atypical anti-
psychotics do not seem to induce depressive episodes
as anti-manic agents, while evidence suggests some
atypical antipsychotics may have antidepressant
(Yatham et al. 2005a) and stabilizing eﬀects (Vieta et al.
2008a).
In recent years, a number of placebo-controlled
RCTs have been conducted. Meta-analytical pro-
cedures allow us to answer questions about overall
magnitude of eﬀect and relative eﬀect by week with
greater statistical power than individual trials. Despite
depression being considered the hallmark of bipolar
disorder (Calabrese et al. 2001) and also a leading
cause of disability and mortality (Mitchell & Malhi,
2004), meta-analyses addressing the eﬃcacy and
eﬀectiveness of atypical antipsychotics in bipolar de-
pression are lacking. Therefore, we conducted the ﬁrst
structured review and meta-analysis of randomized,
placebo-controlled trials of atypical antipsychotics as
monotherapy for the acute treatment of depression in
bipolar I and/or II disorder.
Method
Search strategy
Studies were identiﬁed using searches of PubMed/
Medline with the search terms ‘depression’, ‘placebo’,
and each of the atypical antipsychotics, limited to
randomized, controlled clinical trials ; review of ab-
stracts from the 2003meetings onward of the American
College of Neuropsychiatry, American Psychiatric
Association, and International Conference on Bipolar
Disorder ; and consultations with study investigators
and representatives of pharmaceutical companies that
market atypical antipsychotics. The search included
the period 1994–2007.
Study characteristics
We selected for inclusion randomized, controlled
atypical antipsychotics approved for any indication
by the U.S. Food and Drug Administration since
September 2004 (aripiprazole, asenapine, clozapine,
paliperidone, quetiapine, risperidone, ziprasidone,
olanzapine) and also amisulpiride, licensed in other
countries, with a placebo control group. To avoid
publication bias, we checked the web (www.
clinicaltrials.gov) and contacted all industry sponsors
for ﬁnalized studies. We allowed both monotherapy
studies and studies in which the drug was in combi-
nation with antidepressants, but only trials dealing
with bipolar depression were included.
Data analysis
The primary outcome in all the trials was change
from baseline in Montgomery–Asberg Depression
Rating Scale (MADRS) score at 8 wk and this was also
our criterion. The diﬀerence in change scores between
each drug and its corresponding placebo arm was
computed. That is, how much more improvement was
observed in the drug arm compared to the placebo
arm. Where standard deviations (S.D.) for change
scores were not available, the median S.D. from those
trials where S.D. was reported was used.
We also examined outcomes by response rates,
deﬁned as the proportion of subjects achievingo50%
improvement, and remission rates deﬁned as the
proportion of subjects achieving MADRS f12 at an
endpoint. These endpoint deﬁnitions were homo-
geneous in all trials.
The between-treatment comparisons were esti-
mated by means of the odds ratio (OR) and 95% con-
ﬁdence intervals (95% CI) for the binary variables
(remission and response) and the mean diﬀerence and
95% CI for the MADRS. Since it was considered likely
a priori that not all trials would produce exactly equal
underlying eﬀect sizes, a random-eﬀects model was
considered preferable to a ﬁxed-eﬀects models. The
random-eﬀects model incorporates both within-study
and between-study variance into the estimate of aver-
age treatment eﬀects and is therefore usually more
realistic that the ﬁxed-eﬀects model. We also per-
formed a sensitivity analysis to assess the source of
heterogeneity by excluding the aripiprazole studies,
as they were negative on the primary outcome. In the
only olanzapine trial which included an olanzapine–
ﬂuoxetine combination (OFC) treatment, we only
considered the olanzapine monotherapy arm for the
analysis in order to obtain homogeneous compara-
tive results. The analysis was performed using SAS
version 9.1.3 software (SAS Institute Inc., USA) and
R software version 2.7.0 (R Development Core Team,
Austria). The level of signiﬁcance was established at
the 0.05 level (two-sided).
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Results
The Medline search identiﬁed 15 studies. Only three
of these met the inclusion criteria. Two additional
studies were identiﬁed from a review of meeting pro-
ceedings or consultation with study investigators.
Quetiapine (Calabrese et al. 2005 ; Thase et al. 2006) and
aripiprazole, reporting two studies in one publication
(Thase et al. 2008) were each tested in two trials. One
trial testing olanzapine included a combination ther-
apy (OFC) in addition to the monotherapy and the
placebo arm (Tohen et al. 2003), No placebo-controlled
trials of amisulpride, asenapine, clozapine, paliperi-
done, risperidone or ziprasidone were identiﬁed.
Included studies
A total of ﬁve studies were included. Study charac-
teristics are given in Table 1. In general, monotherapy
trials were of similar size and design, with the excep-
tion of the olanzapine trial, which was larger.
Assessment of depressive symptomswas performed
using the MADRS as a primary variable in all trials.
The baseline depression scores were similar in all
the studies with moderate to severely depressed
patients at inclusion (score range from 28.49 to 32.6).
The duration of all studies was 8 wk. The analysis
included not only the primary variable at endpoint,
but also pooled data by week, in order to assess speed
of action. The aripiprazole trials (Thase et al. 2008) ex-
cluded patients with psychotic features and bipolar II
patients were only enrolled in the quetiapine studies
(32–34%); no trials excluded patients with rapid cyc-
ling, which represented 18–40% of patients in the
studies reporting such data (Calabrese et al. 2005 ;
Thase et al. 2006 ; Tohen et al. 2003).
Assessment of the MADRS scale
Pooled data for each antipsychotic and overall magnitude
of eﬀect
Random-eﬀects estimates of each drug eﬀect (pooled
across all monotherapy and combination studies that
included that drug) and associated 95% CIs are
shown in Fig. 1h. All quetiapine and olanzapine trials
demonstrated signiﬁcant superiority over placebo at
week 8 (i.e. all CIs in the pooled analysis excluded
zero). The overall mean estimate was x3.91 (95% CI
x5.55 to x2.26, p<0.001). Treatment eﬀects exhi-
bited a high degree of heterogeneity on the global
assessment (p=0.013). However, when assessing
the estimates within each drug, the heterogeneity
was substantially reduced [quetiapine : p=0.803;
Table 1. Atypical antipsychotics in the treatment of bipolar depression : placebo-controlled, randomized, monotherapy
and combination therapy studies
Study
Duration
(wk) Comparators
Patients
(n)a
Baseline
MADRS
score
MADRS change
from baseline
at 8 wk
Monotherapy trials
Calabrese et al. (2005) 8 Quetiapine (300 mg) 170 30.3 x16.7
8 Quetiapine (600 mg) 172 30.4 x16.4
8 Placebo 169 30.6 x10.3
Thase et al. (2006) 8 Quetiapine (300 mg) 155 29.9 x16.0
8 Quetiapine (600 mg) 161 31.1 x16.9
8 Placebo 151 29.6 x11.9
Thase et al. (2008) 8 Aripiprazoleb 177 29.1 x12.0
(CN138096) 8 Placebo 164 28.5 x11.4
Thase et al. (2008) 8 Aripiprazoleb 176 29.56 x12.3
(CN138146) 8 Placebo 178 29.35 x11.8
Combination trials
Tohen et al. (2003) 8 Olanzapine 377 32.6 x18.5
8 OFC 370 30.8 x11.9
8 Placebo 86 31.3 x5.19
MADRS, Montgomery–Asberg Depression Rating Scale ; OFC, Olanzapine–ﬂuoxetine combination.
a Number of patients used in eﬃcacy analyses.
b Range 5–30 mg.
Eﬃcacy of antipsychotics in bipolar depression 7
olanzapine : p non-estimable (one study) ; aripiprazole :
p=0.813]. Moreover, when performing the sensi-
tivity analysis excluding the aripiprazole group, the
heterogeneity was then negligible (p=0.302), and the
pooled mean was x4.90 (95% CI x6.21 to x3.59,
p<0.001) (see Fig. 2).
Pooled data for each antipsychotic by week
All of the atypical antipsychotics demonstrated sig-
niﬁcant eﬃcacy from week 1 and throughout the
ﬁrst 6 wk, which was the time with the maximal eﬀect
size reported by all of the studies. From week 6 to
Study
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Pooled
Aripiprazole
   Thase (2008) (CN138096), Aripiprazole 5–30 mg
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Pooled
Pooled (random effects)
–3.47  (–4.53 to –2.42)
–3.30  (–4.69 to –1.91)
–1.79  (–2.99 to –0.59)
–2.88  (–3.57 to –2.19)
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Fig. 1. For legend see next page.
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endpoint quetiapine and olanzapine maintained their
superiority over placebo, but aripiprazole did not
(see Fig. 1).
Assessment of response and remission
Response (overall magnitude for all antipsychotics)
The proportion of patients achieving a clinical re-
sponse, deﬁned as a 50% reduction in MADRS score
from baseline to endpoint, were reported for all trials
by active vs. placebo eﬀect. Random-eﬀects analysis
were pooled, estimated with an overall eﬀect size (OR
0.66, 95% CI 0.49–0.89) (see Fig. 3a).
Treatment eﬀects regarding response exhibited a
high degree of heterogeneity on the global assessment
(p=0.018). However, when assessing the estimates
within each drug, the heterogeneity was substan-
tially reduced [quetiapine : p=0.266 ; olanzapine:
p non-estimable (one study) ; aripiprazole : p=0.5930].
Further, when performing the sensitivity analysis
excluding the aripiprazole group, the heterogeneity
was smaller (p=0.1280), and the pooled OR was 0.55
(95% CI 0.41–0.74, p<0.001) (see Fig. 3b).
Remission (overall magnitude for all antipsychotics)
Proportion of patients achieving a clinical remission,
deﬁned as the proportion of subjects achieving
MADRS f12 at endpoint, were reported for all trials
by active vs. placebo eﬀect. Random-eﬀects analysis
were pooled, estimated with an overall eﬀect size of
0.67 (95% CI 0.45–0.98) (see Fig. 4a).
Treatment eﬀects regarding remission also showed
a high degree of heterogeneity on global assessment
(p=0.0010). However, when assessing the estimates
within each drug, the heterogeneity was substantially
reduced [quetiapine : p=0.119; olanzapine: p non-
estimable (one study) ; aripiprazole : p=0.415].
Moreover, when performing the sensitivity analysis
excluding the aripiprazole group, the heterogeneity
was smaller (p=0.052), and the pooled OR was 0.51
(95% CI 0.35–0.74, p<0.001) (see Fig. 4b).
Discussion
To our knowledge, this is the ﬁrst meta-analysis ad-
dressing the eﬃcacy of atypical antipsychotics in the
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–0.46 (–2.26 to –1.34)
–3.97  (–5.85 to –2.10)
–12 –10 –8 –6 –4 –2 0 1 2 3 4 5
Absolute baseline reduction
Estimates with 95% confidence intervals
Active better Control better Active better Control better
Study
Quetiapine
   Calabrese (2005), Quetiapine 600 mg
   Calabrese (2005), Quetiapine 300 mg
   Thase (2006), Quetiapine 600 mg
   Thase (2006), Quetiapine 300 mg
Pooled
Olanzapine
   Tohen (2003), Olanzapine 5–20 mg
Pooled
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Pooled (random effects)
–5.63  (–7.05 to –4.21)
–3.10  (–5.18 to –1.02)
–1.07  (–2.92 to –0.77)
–3.91  (–5.55 to –2.26)
–12 –10 –8 –6 –4 –2 0 1 2 3 4 5
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(g) (h)
Fig. 1. Random-eﬀects estimates and associated 95% conﬁdence intervals for active vs. placebo eﬀect in
Montgomery–Asberg Depression Rating Scale (MADRS) for quetiapine, olanzapine, and aripiprazole at (a) week 1,
(b) week 2, (c) week 3, (d) week 4, (e) week 5, (f) week 6, (g) week 7, (h) week 8.
Study
Quetiapine
   Calabrese (2005), Quetiapine 600 mg
   Calabrese (2005), Quetiapine 300 mg
   Thase (2006), Quetiapine 600 mg
   Thase (2006), Quetiapine 300 mg
Pooled
Olanzapine
   Tohen (2003), Olanzapine 5–20 mg
Pooled
Pooled (random effects)
–5.63  (–7.05 to –4.21)
–3.10  (–5.18 to –1.02)
–4.90  (–6.21 to –3.59)
–12 –10 –8 –6 –4 –2 0 1 2 3 4 5
Absolute baseline reduction
Estimates with 95% confidence intervals
Active better Control better
Fig. 2. Random-eﬀects estimates of quetiapine and
olanzapine and associated 95% conﬁdence intervals for
active vs. placebo eﬀect in Montgomery–Asberg Depression
Rating Scale (MADRS) at week 8. The aripiprazole group
was excluded from the analysis.
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treatment of bipolar depression. Its results suggest
that some second-generation antipsychotics (quetia-
pine and olanzapine) may additionally represent a
monotherapy management option of bipolar I and/or
II depression. Bipolar disorders present initially with
a depressive episode in >50% of patients, which is
considered the major burden of bipolar disorder
in terms of disability and suicide risk (Colom et al.
2006 ; Daban et al. 2006 ; Mitchell et al. 2008). Currently,
atypical antipsychotics are only considered by treat-
ment guidelines as second- or third-line therapy in
the management of bipolar depression (Fountoulakis
et al. 2007), despite the dearth of positive placebo-
controlled trials with alternative compounds, such
as lithium, lamotrigine or various combinations of
antidepressant and mood-stabilizing agents, which
are still mentioned as ﬁrst-line treatments for bipolar
depression (Yatham et al. 2005a, 2006). Of course,
guidelines and clinicians not only look into eﬃcacy,
but also safety and tolerability as well when prioritiz-
ing treatment options, but it is likely that future
updates of the major guidelines may shift upwards
atypical antipsychotics in bipolar depression in their
suggested algorithms.
We found some atypical antipsychotics (quetiapine
and olanzapine) as monotherapy were signiﬁcantly
more eﬃcacious than placebo (Calabrese et al. 2005;
Thase et al. 2006 ; Tohen et al. 2003), as indicated by
greater reductions in MADRS scores, in the treatment
of acute bipolar depression from week 1 onwards,
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Estimates with 95% confidence intervals
0.1 0.3 1.0 3.0 10.0
(a) (b)
Fig. 3. (a) Random-eﬀects estimates of quetiapine, olanzapine, and aripiprazole and associated 95% conﬁdence intervals
for active vs. placebo eﬀect in response rates. (b) Random-eﬀects estimates excluding the aripiprazole group.
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Pooled (random effects)
0.44  (0.29 to 0.68)
0.67  (0.48 to 0.93)
0.67  (0.45 to 0.98)
1.05  (0.75 to 1.46)
Odds ratio
Active better Placebo better
Estimates with 95% confidence intervals
0.1 0.3 1.0 3.0 10.0
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   Thase (2008) (CN138096), Aripiprazole 5–30 mg
   Thase (2008) (CN138146), Aripiprazole 5–30 mg
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Study
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  Thase (2006), Quetiapine 300 and 600 mg
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Olanzapine
  Tohen (2003), Olanzapine range 5–20 mg
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0.44  (0.29 to 0.68)
0.67  (0.48 to 0.93)
0.51  (0.35 to 0.74)
Odds ratio
Active better Placebo better
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0.1 0.3 1.0 3.0 10.0
(a) (b)
Fig. 4. (a) Random-eﬀects estimates of quetiapine, olanzapine, and aripiprazole and associated 95% conﬁdence intervals
for active vs. placebo eﬀect in remission rates. (b) Random-eﬀects estimates excluding the aripiprazole group.
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except for aripiprazole trials which have shown a 6-wk
limited superiority compared to placebo, decreasing
its eﬀect size at endpoint (Thase et al. 2008).
The very early onset of action of all tested atypical
antipsychotics in the treatment of bipolar depression,
even as monotherapy, may highlight an overlapping
mechanism of action of these drugs as a potential
class eﬀect with independence of the monoaminergic
pathways.
The relevant question of whether initial combi-
nation therapy with a mood stabilizer is superior
to monotherapy with an atypical antipsychotic thus
cannot be answered with the present available data.
The superiority of quetiapine and olanzapine mono-
therapy by week is emphasized by higher response
and remission rates and, except for aripiprazole, lower
drop-out rates due to adverse events. Overall, com-
pletion rates were homogeneous with an average of
y60% for patients under quetiapine and OFC and
slightly less for olanzapine monotherapy and aripi-
prazole treatment groups.
We elected to compare drugs based upon their dif-
ference from placebo, rather than absolute change in
MADRS score, as a means of controlling for study
diﬀerences.
Remission is often considered the most clinically
useful endpoint, deﬁned as an almost complete ab-
sence of mood symptoms, which in our meta-analysis
represented a proportion of patients achieving a
MADRS score of f12. We obtained signiﬁcant pro-
gressive superiority throughout the ﬁrst 6 wk for all
drugs, which was maintained to an endpoint only
by quetiapine and olanzapine.
The homogeneity across the trials’ design and also
in their study sample characteristics were the rule.
Severity of depression at baseline did not show sub-
stantial diﬀerences and placebo response between
studies was surprisingly highly homogeneous and
may be not considered as a source of heterogeneity.
The heterogeneity in this meta-analysis was due to a
diﬀerential eﬀect in the aripiprazole group compared
to the olanzapine and quetiapine groups, but not due
to intra-treatment heterogeneity. Therefore, in our re-
sults, aripiprazole may be considered an important
single source of heterogeneity, therefore there were
no relevant diﬀerences in design among the bipolar
depression studies or in dosage used for the same
drugs.
It should be taken into account that we studied
higher aripiprazole doses as a monotherapy compared
to its use in combination with mood stabilizers. This
fact suggests one potential reason for failed results in
the aripiprazole trials (tolerability issues, especially
akathisia perhaps related to dosing), leading to
drop-outs and also related to diﬀerences in its mech-
anism of action such as too high D2 aﬃnity and low
H1 aﬃnity compared to quetiapine and olanzapine.
The studies also diﬀered in whether they included
rapid-cycling patients or those in mixed states and
also in the proportion of bipolar I or II patients with
psychotic features. However, the exploratory analyses
reported to date suggest little or no diﬀerence in
overall eﬃcacy across these subgroups. Overall, bi-
polar II and rapid-cycling patients highlight lower
eﬀect sizes in primary outcome, although with sig-
niﬁcantly superiority to placebo group in the treat-
ment of bipolar depression. Moreover, the incidence
of treatment-emergent mania was low (from 3.6% for
higher quetiapine doses to a maximum of 5.7% for
olanzapine trials) and not signiﬁcantly diﬀerent from
placebo for any drug.
Regarding tolerability, quetiapine was generally
safe and well tolerated in both tested doses. The most
common adverse eﬀects reported iny30% of patients
were not severe, mostly somnolence and sedation
leading to withdrawal from the study, with most
discontinuations occurring within the ﬁrst week.
Importantly, changes in weight observed in all three
groups were relatively small and did not result in
withdrawal from the study. In fact, weight gain as-
sociated to quetiapine administration was mild and
dose-related, with <9% of patients gaining o7%
from baseline as a clinical meaningfully measurement.
The olanzapine adverse-event proﬁle was consist-
ent with previously reported ﬁndings whereas the
OFC proﬁle was similar to that of olanzapine, except
for higher rates of nausea and diarrhoea. Small but
statistically signiﬁcant mean increases in glucose and
cholesterol levels were also seen. Patients under olan-
zapine treatment reported, as expected, about an 18%
signiﬁcant weight gain compared to the placebo
arm. Nevertheless, only 9% of patients dropped out
in olanzapine trials due to overall adverse events.
The high rates of drop-outs had been related to
aripiprazole trials (study 1, 46.8% vs. 35.1% in placebo
arm and study 2, 41.2% vs. 29.8%, respectively),
and they were more associated to intolerable adverse
events, especially akathisia. No meaningfully clinical
changes on weight were reported
Regarding limitations, there were very few studies
available that currently met the inclusion criteria.
Moreover, the studies included in that meta-analysis
were not adequately powered to detect diﬀerences
in subpopulations of bipolar depression to allow us to
perform subanalysis for bipolar II subtype. Never-
theless, exploratory analysis performed in quetiapine
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trials exerts quite qualitative homogeneous results
for this subpopulation (Suppes et al. 2008). Further
analyses of the pooled data are needed to examine
the therapeutic eﬀect with regard to other clinically
relevant factors such chronicity, sex, history of suicide
attempts or substance abuse.
Moreover adjunctive studies with mood stabilizers
are needed to compare the beneﬁt–risk ratio and also
to conduct more placebo-controlled studies of main-
tenance of antidepressant eﬀect of atypical antipsy-
chotic as monotherapy.
In summary our results suggest some atypical anti-
psychotics (quetiapine and olanzapine) may be con-
sidered as a ﬁrst-line management option in acute
bipolar I and/or II depression, even for poor re-
sponder subgroups such as rapid cyclers and patients
with psychotic features. The question of their class
eﬀect seems to be answered positively regarding
its early onset of action but with diﬀerences in the
magnitude and maintenance of eﬀect. These results
raise questions on the current approach by most
treatment guidelines and on the potential mechanism
of the action involved in the improvement of de-
pressive symptoms in bipolar depression by means of
drugs traditionally considered as antipsychotics.
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